News
MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress. NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical ...
Op zaterdag 28 juni is er de Flashday van INkT KOT in Cimorné in Aalst.
MiNK Therapeutics receives an NIAID grant to develop iNKT cell therapies for preventing graft-versus-host disease in stem cell transplants. MiNK Therapeutics, Inc., a biopharmaceutical company ...
Hosted on MSN2mon
MiNK Therapeutics outlines near-term partnering proposals and reduced cash burn as company advances iNKT programsEarnings Call Insights: MiNK Therapeutics (INKT) Q1 2025 Management View Jennifer Buell, President and CEO, highlighted progress in three critical areas: clinical advancement, capital efficiency ...
MiNK Therapeutics, Inc. (NASDAQ:INKT – Free Report) – Equities research analysts at William Blair issued their Q1 2025 earnings per share estimates for MiNK Therapeutics in a research report ...
A high-level overview of MiNK Therapeutics, Inc. (INKT) stock. View (INKT) real-time stock price, chart, news, analysis, analyst reviews and more.
Check out our INKT stock chart to see a history of performance, current stock value, and a timeline of financial events & indicators for a full analysis today.
Read about MiNK Therapeutics Inc (INKT:XNAS) stock and today's latest news and financial updates. INKT - MiNK Therapeutics Inc News | Morningstar Morningstar brands and products ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback